← Oncology Approval Tracker

FDA DECISION ·

Imjudo + Imfinzi + platinum-based chemotherapy

tremelimumab-actl plus durvalumab and platinum-based chemotherapy · AstraZeneca

FDA approvalNew or expanded indicationNon-small cell lung cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with metastatic NSCLC lacking sensitizing EGFR mutations and ALK genomic alterations receiving tremelimumab, durvalumab and platinum-based chemotherapy.

LAMPGEN ANALYSIS

Why it matters

This approval brings dual-checkpoint blockade with chemotherapy to a defined metastatic lung cancer population.

What research teams should watch

Confirm EGFR and ALK results and distinguish chemotherapy-related and immune-related adverse events during follow-up.

PRIMARY RECORDS

Sources